Edesa Biotech is trading 8.6% up at $5.82 as it extends a technical rebound following a thinly traded selloff in late July.
- The move occurs in the absence of fresh company-specific news, earnings, or FDA updates.
- The stock is rising alongside a broader biotech and equity market rally as traders focus on technical levels.
- Market participants appear to be prioritizing sector momentum over new fundamental developments.